BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32920590)

  • 1. Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis.
    Bin Salman AA; Zaidi ARZ; Altaf SY; AlShehry NF; Tailor IK; Motabi IH; Zaidi SZA
    Am J Case Rep; 2020 Sep; 21():e922971. PubMed ID: 32920590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.
    Gao X; Li J; Wang L; Lin J; Jin H; Xu Y; Wang N; Zhao Y; Liu D; Yu L; Wang Q
    Am J Case Rep; 2016 Oct; 17():793-798. PubMed ID: 27784881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
    Qing X; Qing A; Ji P; French SW; Mason H
    Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated central nervous system blast crisis in chronic myeloid leukemia.
    Rajappa S; Uppin SG; Raghunadharao D; Rao IS; Surath A
    Hematol Oncol; 2004 Dec; 22(4):179-81. PubMed ID: 15995975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
    Slezáková K; Mistrík M; Bátorová A
    Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant L248V With E225V Mutation in the BCR-ABL Gene Associated With Rapid Chronic Myeloid Leukemia Lymphoid Blast Crisis.
    Tungjitviboonkun S; Wachirapornpruet P; Unsuwan S
    Cureus; 2024 Apr; 16(4):e58972. PubMed ID: 38800235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.
    Janjetovic S; Asemissen AM; Dicker F; Binder M; Dierlamm J; Bokemeyer C; Schafhausen P
    Tumori; 2019 Dec; 105(6):NP8-NP11. PubMed ID: 30935343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
    Boudiaf H; Ezziane K; Rouis NO; Himrane M; Hakem S; Benchabane H; Boukhelal H; Arous R; Chikhi L
    Pan Afr Med J; 2020; 36():142. PubMed ID: 32874406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
    Lee MH; Song A; Li JY
    Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.